Innovation Pharmaceuticals Inc (IPIX)

[slcimmuno]

another B-OM Comp - a bit throwback (2004) MGI / Saforis

looking like any milestone tied to Approval should be closer to $30m (saforis, oragenics) than $15m (valdive)

and re the competition -- not even close. swish-spit and IPIX is going after Prevention of Sev OM, not reduction in duration. plus, most others in trials are IV administered.

just need topline to deliver strong results, followed by breakthrough, and hopefully in partnership, and off to races we go.

-

Through the merger, the Company acquired all of the ownership interests in Aesgen from its securityholders. The Company paid $32 million at the closing as merger consideration to Aesgen’s former securityholders. The Company is also obligated to pay $33 Million to Aesgen’s former securityholders upon FDA approval of Aesgen’s lead product currently known as Saforis (TM), and an additional $25 million in the event that net sales of Aesgen products containing L-Glutamine, including Saforis, exceed $50 million in the second year after commercial launch of Saforis. After aggregate net sales of Saforis exceed $50 million, the Company will also be obligated to pay Aesgen’s former securityholders a 5% royalty on net sales of Saforis through the end of the ten-year period commencing upon commercial launch of Saforis.

https://www.sec.gov/Archives/edgar/data/702131/000119312504165663/d8k.htm